HLA-G and ovarian carcinoma: HLA‐G and/or PD‐L1 expressing cancer cells including NSCLC A549, breast cancer MDA‐MB‐231, ovarian cancer SK‐OV‐3, and hypopharyngeal tumor FaDu cell lines were used.